News

Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a…

Akcea Therapeutics UK Ltd., has announced that NICE has issued a positive Final Evaluation Document (FED) for Tegsedi(tm) (inotersen) for the treatment of stage 1…

Prothena Corporation PLC, a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amyloidosis study of NEOD001 (birtamimab) in…

Treatment with the investigational drug tafamidis was associated with a reduction in all-cause mortality and cardiovascular hospitalizations in patients with…

The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment-the first therapy indicated for…

The US Food and Drug Administration (FDA) has approved inotersen (Tegsedi, Akcea Therapeutics and Ionis Pharmaceuticals) for the treatment of polyneuropathy (PN) in…

A new hereditary ATTR (hATTR) amyloidosis treatment, inotersen, an investigational antisense drug, may not be far from a US Food and Drug Administration (FDA)…

Amyloidosis is a rare condition that used to almost always be fatal, but doctors are finally making progress in treating it. "I had so many symptoms, and I really…

Updated research regarding the ANDROMEDA study presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicated the…

Amyloidosis is a disorder in which certain proteins abnormally change their shape in a process called "misfolding." The misfolded proteins accumulate together and…